- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Affordable Care Act Projected to Drive Up Prescription Drug Spending in Coming Years
Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.
While the overall benefits of the Affordable Care Act (ACA) are still hotly debated, there is little doubt the landmark legislation will lead to a boon for the pharmaceutical industry and the specialty drug market, according to the latest drug trend update from the Catamaran Corporation.
Catamaran, which provides pharmacy benefit management (PBM) services and technology, recently released a trend report updated for the first half of 2014 that calls for an upward trajectory for pharmacy spending due to the combined impact of health care reform and a robust drug pipeline. Technological advances and a growing demand for specialty therapies is expected to drive specialty medications to account for approximately 40% of all pharmacy spending by 2016.
“The impact of health care reform will become readily apparent across pharmacy purchasing and benefits,” the report states. “US spending on prescription drugs is estimated to increase in the retail space by $227 billion between 2010 and 2020.”
Read the full story here: http://bit.ly/1uncrGT
Source: Specialty Pharmacy Times
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
